Real Numbers

Rawlings, Kelly
May 2013
Diabetes Forecast;May2013, Vol. 66 Issue 5, p9
The author discusses issues related to diabetes and states that according to American Diabetes Association the total economic cost of diagnosed diabetes in the U.S. is estimated at 245 billion U.S. dollars. She also states that large proportion of medical care cost related to diabetes come from hospitalization, complications and treatment. She finally suggests for reducing cost and harm from diabetes through awareness, advocacy and preventive treatment.


Related Articles

  • Diabetes model predicts costs and consequences for the US.  // PharmacoEconomics & Outcomes News;5/17/2008, Issue 553, p7 

    The article discusses the research "Drug Combo Could Lower Diabetes Complications and Costs" released by the American Diabetes Association. According to the research, the risk of heart attack is lowered by forty-percent given that diabetes is cured. It also found that providing optimal care...

  • Preventing the tragedy of railway suicides. Bhui, Kamaldeep // Mental Health Today;Mar/Apr2014, p24 

    No abstract available.

  • The economic burden of diabetes. Simonson, Donald C. // Clinical Diabetes;1999, Vol. 17 Issue 1, p47 

    Comments on the study concerning the economic consequences of diabetes mellitus in the United States in 1997. Diabetes as a significant public health problem; Direct medical and indirect expenditures attributable to diabetes; Changes in the health care delivery in the US; Utilization of health...

  • SCOTUS Does No Harm. WINDISH, JOE // Moderate Voice;6/28/2012, p20 

    The article presents the author's insights on the application of political economist John Stuart Mill's harm principle on the U.S. healthcare mandate. The author says that millions of Americans do not pay insurance premiums. He explains that under Mill's harm principle, the U.S. government has...

  • Is It Worth the Risk? MORRISSEY, JOHN // H&HN: Hospitals & Health Networks;Jun2014, Vol. 88 Issue 6, p50 

    The article investigates the necessity of frequently used diagnostics that could increase the risk and expense of patients. Topics discussed include several services being reviewed by the American Hospital Association such as blood management, antibiotic stewardship, proper use of intensive care...

  • Harm-reduction activism: a case study of an unsanctioned user-run safe injection site. Kerr, Thomas; Oleson, Megan; Wood, Evan // Canadian HIV/AIDS Policy & Law Review;Aug2004, Vol. 9 Issue 2, p13 

    Presents a case study of the establishment of an unsanctioned safe injection site in Vancouver, Canada, for injection drug users by a group of activists in 2003. Operation of the site for 181 days, despite police harassment and limited financial support; Report that Vancouver has been the site...

  • ADA Says Disease Is Taking an Increasingly Heavy Economic.  // Chain Drug Review;6/3/2013, Vol. 35 Issue 9, p57 

    The article reflects on a research released by the American Diabetes Association (ADA) that presents an examination of the increased financial cost and use of health resources due to diabetes in 2012 and reveals that diagnosed diabetes cost the U.S. an estimated 245 billion U.S. dollars in 2012.

  • $245 Billion Spent on Diabetes in 2012. Resnick, Helaine E. // Diabetes Care;Apr20123, Vol. 36 Issue 4, p771 

    The article reports that an economic analysis from the American Diabetes Association (ADA) has revealed that the economic burden of diabetes is at 245 billion U.S. dollars in 2012.

  • ADA panel: Screen diabetics annually for lipid disorders.  // Geriatrics;Aug93, Vol. 48 Issue 8, p16 

    Reports on the recommendations of the American Diabetes Association regarding care of adult diabetic patients. Screening patients annually for lipid levels and treating lipid disorders more aggressively; Major risk factors for macrovascular complications in the patient; Cornerstones of treatment.

  • Spotlight: FDA Acts to Reduce Harm from Opioid Drugs.  // Dental Assistant;May/Jun2011, Vol. 80 Issue 3, p44 

    The article offers information on the Risk Evaluation and Mitigation Strategy (REMS), a risk education program of U.S. Food and Drug Administration as part of the effort of the White House to reduce the misuse, abuse, and misprescription of opioids drugs. It says that REMS will focus on...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics